drugset / Trial / NCT01548430
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
RandomizedSingle-groupDouble-blind
Summary
The purpose of the study is to examine the safety, tolerability, immunogenicity and pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive impairment.
Timeline
- Start
- 2011-10
- Primary completion
- 2013-02
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TTP4000 | Unknown | 1 mg/kg | Subcutaneous |
| Subject | TTP4000 | Unknown | 3 mg/kg | Subcutaneous |